RT Journal Article
SR Electronic
A1 Buckley, Rita
T1 Neutral Outcomes but Important Insights from FOCUS-CCTRN
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 4
SP 22
OP 22
DO 10.1177/155989771204016
UL http://mdc.sagepub.com/content/12/4/22.abstract
AB Cell therapy has emerged as an exciting and innovative approach for treating patients with advanced ischemic heart disease, including those with refractory angina and/or heart failure [Perin EC et al. JAMA 2012]. The FOCUS-CCTRN trial [NCT00824005] was designed to evaluate the safety and efficacy of bone marrow mononuclear cells in patients with chronic ischemic heart disease and left ventricular dysfunction with no other revascularization options.